ANI PHARMACEUTICALS, INC Deferred Tax Liabilities, Intangible Assets
ANI PHARMACEUTICALS, INC (ANIP) had Deferred Tax Liabilities, Intangible Assets of $7.36 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2026-02-27
- 2025-12-31: Deferred Tax Liabilities, Intangible Assets $7.36M.
- 2024-12-31: Deferred Tax Liabilities, Intangible Assets $12.54M.
- 2023-12-31: Deferred Tax Liabilities, Intangible Assets $0.00.
- 2021-12-31: Deferred Tax Liabilities, Intangible Assets $11.00K.
| Period end | Deferred Tax Liabilities, Intangible Assets | Deferred Tax Liabilities, Intangible Assets as first filed |
|---|---|---|
| 2025-12-31 | $7.36M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $12.54M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $0.00 10-K · filed 2025-02-28 | |
| 2021-12-31 | $11.00K 10-K · filed 2023-03-09 | |
| 2020-12-31 | $11.00K 10-K · filed 2022-03-15 | |
| 2019-12-31 | $13.00K 10-K · filed 2021-03-11 | |
| 2018-12-31 | $11.00K 10-K · filed 2020-02-27 | |
| 2017-12-31 | $11.00K 10-K · filed 2019-02-27 | |
| 2016-12-31 | $353.00K 10-K · filed 2018-02-27 | |
| 2015-12-31 | $3.13M 10-K · filed 2017-03-02 | $0.00 10-K · filed 2016-02-23 |
| 2014-12-31 | $467.00K 10-K · filed 2016-02-23 | |
| 2013-12-31 | $526.00K 10-K · filed 2015-02-23 | |
| 2012-12-31 | $0.00 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |